The FDA on July 8 approved a label expansion for Horizon Therapeutics’ Krystexxa. The injectable, in combination with methotrexate, will be the first treatment available for uncontrolled gout in patients whose symptoms have not responded to other therapies. The drug was first approved in 2010. For the treatment of gouty arthritis, Krystexxa currently holds covered or better status for 57% of all insured lives under the pharmacy benefit. Krystexxa is not covered for 34% of lives.
Source: MMIT Analytics, as of 7/13/22